CLINICAL TRIALS PROFILE FOR IMCIVREE
✉ Email this page to a colleague
All Clinical Trials for IMCIVREE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05774756 ↗ | A Trial of Setmelanotide in Acquired Hypothalamic Obesity | Recruiting | Rhythm Pharmaceuticals, Inc. | Phase 3 | 2023-03-26 | The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 60 weeks. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for IMCIVREE
Condition Name
Clinical Trial Locations for IMCIVREE
Trials by Country
Clinical Trial Progress for IMCIVREE
Clinical Trial Phase
Clinical Trial Sponsors for IMCIVREE
Sponsor Name